Beranda › Limfoma Non-Hodgkin › Georgia
Uji klinis Limfoma Non-Hodgkin di Georgia
21 studi untuk Limfoma Non-Hodgkin mencari peserta di lokasi di Georgia.
Kota di Georgia
Teks studi resmi (Bahasa Inggris)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT05006716Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion, Savannah
- dan 3 lainnya
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT02693535A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Emory University Hospital, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07226843Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT03666000Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Augusta University Medical Center, Augusta
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Winship Cancer Institute of Emory University, Atlanta
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northside Hospital, Atlanta
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07188558A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07020533DALY II USA/ MB-CART2019.1 for DLBCL
- Winship Cancer Institute of Emory University, Atlanta
- Georgia Cancer Center at Augusta University, Augusta
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's Healthcare of Atlanta, Atlanta
- Northside Hospital, Atlanta
- Georgia Cancer Center at Augusta University Health, Augusta
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Emory Winship Cancer Institute, Atlanta
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jun 2026 · NCT04068597SynKIR-310 for Relapsed/Refractory B-NHL
- Winship Cancer Institute of Emory University, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Apr 2026 · NCT06544265A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- City of Hope Atlanta, Newnan
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06915246Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Northside Hospital, Atlanta
- Northside Hospital - Duluth, Duluth
- Liberty County Cancer Care, Hinesville
- dan 4 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
Menerima pesertaFase 2Sukarelawan sehat diterima
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 10 Mar 2026 · NCT06059391A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- The Emory Clinic, Atlanta
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Mar 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- The Emory Clinic, Atlanta
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Mar 2026 · NCT06876662SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Atlanta
- Massive Bio SYNERGY-AI site, Savannah
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Emory University Hospital, Atlanta
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2025 · NCT06119685Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.